RISK/TOX CHIP PROGRAM

风险/毒物芯片计划

• 批准号: 2864884
• 负责人: MICHAEL E. HOGAN
• 金额: $ 60万
• 依托单位: GENOMETRIX, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2864884
• 关键词: alleles; biomedical automation; biomedical equipment; biomedical equipment development; gene frequency; genetic polymorphism; human genetic material tag; human population genetics; human tissue; lung neoplasms; neoplasm /cancer genetics; nucleic acid sequence; polymerase chain reaction

DESCRIPTION: (Applicant's abstract) We will develop the instrumentation, the techniques and the DNA microarray technology to enable very large scale analysis of inherited genetic variation, on as many as 50 genes at a time. We refer to such testing as population-wide "allele signature" analysis. Below we list the specific aims of the research plan. SA 1. We will optimize DNA microarray fabrication so that it can supply up to 1,000,000 microarrays per year for allele signature analysis. We focus our development and testing on a panel of approximately 100 alleles chosen with reference to their importance in chemical toxicology and environmental carcinogenesis of the lung. We refer to this as the "Risk-fox Chip." SA 2. We will develop procedures and automated workstations which can extract DNA and perform the requisite microarray hybridization, detection and data analysis on up 950,000 blood samples per year. The workstations will be based upon the use of a Beckman robot, coupled to a Sagian robot arm and will exploit recent advances made in the theory of nucleic acid extraction and highly multiplex DNA amplification. SA 3 & SA 4. First, traditional methods will be used to measure the genotype of a set of about 100 DNA samples from blood, for each of the 100 alleles on the Risk-Tox Chip. These standardized DNA samples will be then used to validate the performance of the Risk-tox Chip, and to test the approaches chosen for automated sample preparation, hybridization and detection. Secondly, the high throughput automation procedures and the quality of the DNA microarray product will be validated on a twenty-fold larger set of blood samples which will have been archived by the National Center for Toxicological Research and by M.D. Anderson Cancer Center. Special emphasis will be placed on development of the informatics required for organization of very large-scale blood and DNA sample archives and the mathematical methods required to evaluate the predictive power of an allele signature in the very large scale, population based applications which we envision.

描述：（申请人摘要）我们将开发仪器， 这些技术和DNA微阵列技术可以使大规模的 分析遗传变异，一次多达50个基因。 我们将这种测试称为群体范围的“等位基因签名”分析。 下面我们列出研究计划的具体目标。 SA 1. 我们将优化DNA微阵列的制造， 到每年100万个微阵列用于等位基因签名分析。 我们专注 我们对一组大约100个等位基因的开发和测试， 鉴于其在化学毒理学和环境中的重要性 肺癌的发生 我们称之为“风险狐狸芯片”。" SA 2. 我们将开发程序和自动化工作站， 提取DNA并进行必要的微阵列杂交、检测 以及每年多达95万份血液样本的数据分析。 工作站 将基于使用贝克曼机器人，耦合到Sagian机器人手臂 并将利用核酸理论的最新进展 提取和高度多重DNA扩增。 SA 3和SA 4。 首先，将使用传统方法来测量 一组约100个来自血液的DNA样品的基因型，对于100个 风险毒理芯片上的等位基因 这些标准化的DNA样本 用于验证风险毒性芯片的性能，并测试 选择用于自动化样品制备、杂交 侦测 其次，高通量自动化程序和 DNA微阵列产品的质量将在20倍的 更大的一组血液样本，将由国家 毒理学研究中心和医学博士。安德森癌症中心。 将特别强调发展所需的信息学 组织非常大规模的血液和DNA样本档案， 评估等位基因预测能力所需的数学方法 签名在非常大的规模，人口为基础的应用程序，我们 想象